ANKHD1
Ankyrin repeat and KH domain-containing protein 1
You are using an outdated browser. Please upgrade your browser to improve your experience.
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor perturbation | 0.88 | ||
transcription factor binding site profile | 0.86 | ||
interacting protein | 0.83 | ||
histone modification site profile | 0.8 | ||
kinase perturbation | 0.76 | ||
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
- OR - satisfy the following criterion:
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Target has at least one approved drug - AND - satisfies the preceding conditions
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from High Throughput Direct Assay (HDA) | UniProtKB | |||
GWAS Trait | EFO ID | Study Count | SNP Count | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
---|---|---|---|---|---|---|---|---|---|
intelligence | 3 | 5 | 2 | 5.9 | 57.7 | ||||
white matter integrity | 2 | 1 | 2 | 35 | |||||
creatine kinase measurement | 1 | 1 | 1 | 31.4 | |||||
monocyte count | 1 | 1 | 1 | 13.8 | |||||
inflammatory biomarker measurement | 1 | 1 | 0 | 125.7 | 6.1 | ||||
GWAS Trait | EFO ID | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
---|---|---|---|---|---|---|---|
intelligence | 2 | 5.9 | 57.7 | ||||
white matter integrity | 2 | 35 | |||||
creatine kinase measurement | 1 | 31.4 | |||||
monocyte count | 1 | 13.8 | |||||
inflammatory biomarker measurement | 0 | 125.7 | 6.1 | ||||
PMID | Year | Title |
---|